Objective: To determine the short-term safety of high-dose intravenous methylprednisolone in acute attacks of multiple sclerosis (MS).

Method: In a prospective study, we evaluated the patients with MS who received high-dose intravenous methylprednisolone for acute attacks. By repeated physical and laboratory examinations and history taking, patients were assessed for adverse effects that would be related to pulse therapy before, within, and 3 months after the treatment.

Results: Sixty-four patients with definite MS with acute attack were enrolled in the study in which 46 (71.9%) were female. Fifty-eight patients (90.6%) developed minor adverse effects of which the most common were palpitation, flashing, dyspepsia, insomnia, and virulent taste. On the other hand, 12 patients (18.75%) developed major adverse effects, and the most common was sinus tachycardia. Six patients (9.3%) were without any adverse effects. There was a significant relationship between the dosage of methylprednisolone (3 or 5 g) and the occurrence of major adverse effects (P = 0.025).

Conclusion: This study approved that high-dose intravenous methylprednisolone is a safe treatment in MS attacks and the short-term adverse effects were mostly minor and transient.

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNF.0b013e3182764f91DOI Listing

Publication Analysis

Top Keywords

adverse effects
24
high-dose intravenous
12
intravenous methylprednisolone
12
short-term safety
8
multiple sclerosis
8
methylprednisolone acute
8
acute attacks
8
effects common
8
major adverse
8
patients
6

Similar Publications

Objective: To evaluate whether there is an association between maternal mental health, purchase of psychotropic drugs, socioeconomic status and major congenital anomalies in offspring.

Methods: A register-based cohort study of 6189 Finnish primiparous women who had a singleton delivery between 2009 and 2015. Data on pregnancy and delivery outcomes, psychiatric diagnosis, prescription drug purchases and offspring congenital anomalies were obtained from Finnish national registers.

View Article and Find Full Text PDF

Cancer is one of the most devastating illnesses in the world, impacting millions of individuals every year. Despite various therapies, the final effect is unsatisfactory. Chemotherapy currently dominates as the primary option of treatment.

View Article and Find Full Text PDF

Delineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.

Curr Drug Discov Technol

December 2024

Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, 603203, India.

Background: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel.

View Article and Find Full Text PDF

Identification and Characterization of a Protease Producing Strain From Tannery Waste for Efficient Dehairing of Goat Skin.

Biomed Res Int

January 2025

Center for Personalized Nanomedicine, Australian Institute for Bioengineering & Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland, Australia.

Environmental pollution has been a significant concern for the last few years. The leather industry significantly contributes to the economy but is one of Bangladesh's most prominent polluting industries. It is also responsible for several severe diseases such as cancer, lung diseases, and heart diseases of leather workers because they use bleaching agents and chemicals, and these have numerous adverse effects on human health.

View Article and Find Full Text PDF

Introduction: Age-associated depletion in nicotinamide adenine dinucleotide (NAD+) concentrations has been implicated in metabolic, cardiovascular, and neurodegenerative disorders. Supplementation with NAD+ precursors, such as nicotinamide riboside (NR), offers a potential therapeutic avenue against neurodegenerative pathologies in aging, Alzheimer's disease, and related dementias. A crossover, double-blind, randomized placebo (PBO) controlled trial was conducted to test the safety and efficacy of 8 weeks' active treatment with NR (1 g/day) on cognition and plasma AD biomarkers in older adults with subjective cognitive decline and mild cognitive impairment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!